Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00261
|
|||||
| Drug Name |
Lenalidomide
|
|||||
| Synonyms |
3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione; 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(7-Amino-3-oxo-1H-isoindol-2-yl)-piperidine-2,6-dione; 3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione; ALBB-015321; CC 5013; CC-5013; CC-5013, Revlimid, Lenalidomide; CC5013; CDC 501; CDC-501; CDC-5013; Celgene brand of lenalidomide; ENMD-0997; IMID-5013; IMiD3; IMiD3cpd; Lenalidomide (Immunomodulator); Lenalidomide (USAN/INN); Lenalidomide [USAN]; Revamid; Revimid; Revlimid; Revlimid (Celgene); Revlimid (TN); Thalidomide analog CC-5013
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Anaemia [ICD11:3A9Z] | Approved | [1] | |||
| Multiple myeloma [ICD11:2A83] | Approved | [1] | ||||
| Therapeutic Class |
Anticancer Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C13H13N3O3
|
|||||
| Canonical SMILES |
C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N
|
|||||
| InChI |
InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)
|
|||||
| InChIKey |
GOTYRUGSSMKFNF-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 191732-72-6
|
|||||
| Pharmaceutical Properties | Molecular Weight | 259.26 | Topological Polar Surface Area | 92.5 | ||
| Heavy Atom Count | 19 | Rotatable Bond Count | 1 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 4 | |||
| XLogP |
-0.5
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103222228
,109693476
,113461419
,117883377
,119509589
,12015317
,124409664
,124756946
,124893327
,124893328
,125163752
,125343917
,126591352
,126628313
,126652519
,126667069
,127984536
,134338492
,134964412
,135134887
,135600354
,135610831
,135683667
,136367898
,136374703
,136949134
,137000301
,137039885
,140119412
,143496160
,144116136
,144206045
,14847985
,152237735
,152258939
,160647784
,30420059
,46505725
,47206522
,50067858
,50112744
,50484855
,53786789
,57399776
,81092908
,85174578
,91148448
,92719197
,9372858
,99437218
|
|||||
| ChEBI ID |
ChEBI:63791
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Lenalidomide was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB00480) | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.